Roanna Ruiz
Stock Analyst at Leerink Partners
(0.92)
# 3,892
Out of 5,030 analysts
58
Total ratings
36.59%
Success rate
-13.58%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $9.14 | -1.53% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $2.92 | +139.73% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $10.08 | +78.57% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.47 | -31.97% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.80 | +244.83% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $10.11 | +167.06% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $7.01 | +85.45% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.05 | +177.23% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $432.69 | -23.73% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $58.96 | -1.63% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $79.47 | -68.54% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $11.38 | +330.58% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.12 | +92.31% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $36.47 | -47.90% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $56.36 | +112.92% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $10.51 | +375.74% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $20.07 | +99.30% | 6 | Oct 19, 2022 |
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $9.14
Upside: -1.53%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $2.92
Upside: +139.73%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $10.08
Upside: +78.57%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.47
Upside: -31.97%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.80
Upside: +244.83%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $10.11
Upside: +167.06%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $7.01
Upside: +85.45%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.05
Upside: +177.23%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $432.69
Upside: -23.73%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $58.96
Upside: -1.63%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $79.47
Upside: -68.54%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $11.38
Upside: +330.58%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.12
Upside: +92.31%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $36.47
Upside: -47.90%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $56.36
Upside: +112.92%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $10.51
Upside: +375.74%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $20.07
Upside: +99.30%